The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis.
The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis.
复制标题
DOI：
10.1001/jamaneurol.2014.1472
复制
发表时间：
2014-11
期刊：
影响因子：
29
通讯作者：
Monson, Nancy L.
中科院分区：
文献类型：
--
作者：
Ireland, Sara J.;Guzman, Alyssa A.;O'Brien, Dina E.;Hughes, Samuel;Greenberg, Benjamin;Flores, Angela;Graves, Donna;Remington, Gina;Frohman, Elliot M.;Davis, Laurie S.;Monson, Nancy L.
据我们所知，这项研究描述了以前未知的醋酸格拉替默治疗对复发-缓解型多发性硬化症（MS）患者B细胞的影响。为了确定醋酸格拉替默治疗是否能使MS患者失调的b细胞增殖和细胞因子产生正常化，我们在德克萨斯大学西南医学中心多发性硬化症诊所招募了22名接受醋酸格拉替默治疗的MS患者和22名首次接受治疗的MS患者。健康献血者的细胞样本从HemaCare或Carter血库获得。未接受治疗的多发性硬化症患者在研究前至少3个月未接受任何疾病改善治疗。在研究开始时服用醋酸格拉替默至少3个月。b细胞表型和增殖与免疫球蛋白和细胞因子分泌。在接受醋酸格拉替默治疗的患者中，观察到外周B细胞白细胞介素10的产生恢复，并且在接受治疗少于32个月的患者中，白细胞介素6的产生显着减少。此外，在服用醋酸格拉替默的患者体内获得的体外活化B细胞中，对高剂量CD40L的增殖反应被改变，免疫球蛋白的产生也增加。醋酸格拉替默治疗重塑了b细胞室的组成，影响细胞因子的分泌和免疫球蛋白的产生。这些数据表明，醋酸格拉替默治疗影响MS中b细胞功能失调的几个方面，这可能有助于醋酸格拉替默的治疗机制。
This study describes what is, to our knowledge, the previously unknown effect of glatiramer acetate therapy on B cells in patients with relapsing-remitting multiple sclerosis (MS). To determine whether glatiramer acetate therapy normalizes dysregulated B-cell proliferation and cytokine production in patients with MS. Twenty-two patients with MS who were receiving glatiramer acetate therapy and 22 treatment-naive patients with MS were recruited at The University of Texas Southwestern Medical Center multiple sclerosis clinic. Cell samples from healthy donors were obtained from HemaCare or Carter Blood Bank. Treatment-naive patients with MS had not received any disease-modifying therapies for at least 3 months before the study. Glatiramer acetate therapy for at least 3 months at the time of the study. B-cell phenotype and proliferation and immunoglobulin and cytokine secretion. A restoration of interleukin 10 production by peripheral B cells was observed in patients undergoing glatiramer acetate therapy as well as a significant reduction of interleukin 6 production in a subset of patients who received therapy for less than 32 months. Furthermore, proliferation in response to high-dose Cluster of Differentiation 40 Ligand (CD40L) was altered and immunoglobulin production was elevated in in vitro–activated B cells obtained from patients who received glatiramer acetate. Glatiramer acetate therapy remodels the composition of the B-cell compartment and influences cytokine secretion and immunoglobulin production. These data suggest that glatiramer acetate therapy affects several aspects of dysregulated B-cell function in MS that may contribute to the therapeutic mechanisms of glatiramer acetate.
登录
查看更多内容
影响因子：
--
作者：
Anat, Achiron;Anna, Feldman;Michael, Gurevich
通讯作者：
Michael, Gurevich
DOI：
10.4049/jimmunol.1102500
发表时间：
2012-02-01
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Maseda D;Smith SH;DiLillo DJ;Bryant JM;Candando KM;Weaver CT;Tedder TF
通讯作者：
Tedder TF
影响因子：
5.4
作者：
Harp, Christopher T.;Ireland, Sara;Davis, Laurie S.;Remington, Gina;Cassidy, Bonnie;Cravens, Petra D.;Stuve, Olaf;Lovett-Racke, Amy E.;Eagar, Todd N.;Greenberg, Benjamin M.;Racke, Michael K.;Cowell, Lindsay G.;Karandikar, Nitin J.;Frohman, Elliot M.;Monson, Nancy L.
通讯作者：
Monson, Nancy L.
DOI：
10.1084/jem.20111675
发表时间：
2012-05-07
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Barr TA;Shen P;Brown S;Lampropoulou V;Roch T;Lawrie S;Fan B;O'Connor RA;Anderton SM;Bar-Or A;Fillatreau S;Gray D
通讯作者：
Gray D
影响因子：
2.6
作者：
Dörner, T;Lipsky, P
通讯作者：
Lipsky, P